Early access
Sign in
Active, not recruitingPhase 3

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Key facts

Who runs it
Vertex Pharmaceuticals Incorporated
Where
Albuquerque, Anderson, Anniston, Baton Rouge, Beachwood, Bellevue, Boston, Brooklyn, Charleston, Chicago, Cincinnati, Coral Gables, Covington, Dallas, Daphne, Dayton, Decatur, DeLand, Doral, East Greenwich, East Syracuse, Englewood, Evansville, Fort Myers, Fresno, Hallandale, Hazelwood, Jacksonville, Kansas City, Largo, Lexington, Long Beach, Los Angeles, Maitland, Marlton, Medford, Media, Meridian, Miami Lakes, Morehead City, New Port Richey, New York, Norfolk, Orlando, Pomona, Raleigh, Richmond, Round Rock, Sacramento, Salt Lake City, San Antonio, San Bernardino, Scottsdale, Spartanburg, Thousand Oaks, Tinley Park, Waco, Waltham, Washington D.C., West Jordan, Wichita, Winston-Salem, and Winter Park, United StatesSee the 65 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
455 people enrolled
Started
18 Dec 2024
Expected to end
25 Jan 2027
Type of study
Interventional
Treatments tested
  • Suzetrigine
Record updated
30 October 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Completed the final visit in the Treatment Period (i.e., Week 12) and subsequent 7-day period (to allow for taper of blinded capsule study drug) in a parent study such as VX24-548-110 or VX24-548-111

Who cannot take part

  • Current participation in an investigational drug trial (other than a parent study); Other protocol defined Inclusion/Exclusion criteria may apply
  • History of drug intolerance in a parent study that would pose an additional risk to the participant in the opinion of the investigator
  • Any sensory abnormality (excluding DPN)

Where in United States

  • Velocity Clinical Research - AlbuquerqueAlbuquerque, United States
  • Synexus Clinical Research- AndersonAnderson, United States
  • Pinnacle Research Group, LLCAnniston, United States
  • Velocity Clinical Research - Baton RougeBaton Rouge, United States
  • Velocity Clinical Research, ClevelandBeachwood, United States
  • Northwest Clinical Research Center (NWCRC)Bellevue, United States
  • Mass General Brigham - Brigham and Women's Hospital - Main CampusBoston, United States
  • Swift Clinical OpCo, IncBrooklyn, United States
  • Clinical Trials of South Carolina - CharlestonCharleston, United States
  • M3 Wake Research - CharlestonCharleston, United States
  • Feinberg School of Medicine - AnesthesiologyChicago, United States
  • Synexus Clinical Research - CincinnatiCincinnati, United States
  • AMR MiamiCoral Gables, United States
  • Tandem Clinical Research- CovingtonCovington, United States
  • Zenos Clinical ResearchDallas, United States
  • AMR Daphne, ALDaphne, United States
  • META Medical Research InstituteDayton, United States
  • Accel Research - DecaturDecatur, United States
  • Accel Research - DelandDeLand, United States
  • Suncoast Research Associates - MiamiDoral, United States
  • Velocity Clinical Research, ProvidenceEast Greenwich, United States
  • Velocity Clinical Research, SyracuseEast Syracuse, United States
  • Velocity Clinical Research, DenverEnglewood, United States
  • Synexus Clinical Research - EvansvilleEvansville, United States
  • AMR Fort Myers (The Clinical Study Center)Fort Myers, United States
  • Neuro-Pain Medical CenterFresno, United States
  • Velocity Clinical Research, Hallandale BeachHallandale, United States
  • Healthcare Research Network - Hazelwood MOHazelwood, United States
  • CNS Healthcare - JacksonvilleJacksonville, United States
  • AMR Kansas CityKansas City, United States
  • Accel Research Site - St. Petersburg/LargoLargo, United States
  • AMR LexingtonLexington, United States
  • Long Beach Research InstituteLong Beach, United States
  • Angel City Research, Inc.Los Angeles, United States
  • Accel Research Sites - MaitlandMaitland, United States
  • HRI - Hassman Research InstituteMarlton, United States
  • Velocity Clinical Research, MedfordMedford, United States
  • Suburban Research Associates - MediaMedia, United States
  • Velocity Clinical Research, BoiseMeridian, United States
  • 3Sync Research - Miami LakesMiami Lakes, United States
  • West Clinical ResearchMorehead City, United States
  • Suncoast Clinical Research - New Port RicheyNew Port Richey, United States
  • Columbia Presbyterian - The Neurological Institute of New YorkNew York, United States
  • Synexus Clinical Research - New York (DRS)New York, United States
  • Velocity Clinical Research - NorfolkNorfolk, United States
  • Conquest Clinical Research - Orlando - NeuroOrlando, United States
  • Empire Clinical ResearchPomona, United States
  • Eximia Research - RaleighRaleigh, United States
  • Dominion Medical Associates, Inc.Richmond, United States
  • Be Well Clinical Studies - AustinRound Rock, United States
  • Clinical Trials ResearchSacramento, United States
  • Kalo Clinical Research - Salt Lake CitySalt Lake City, United States
  • San Antonio Clinical TrialsSan Antonio, United States
  • Velocity Clinical Research, San BernardinoSan Bernardino, United States
  • Scottsdale Clinical TrialsScottsdale, United States
  • Velocity Clinical Research, SpartanburgSpartanburg, United States
  • SCLA Management - Pain Management and Injury ReliefThousand Oaks, United States
  • Healthcare Research Network - Flossmoor ILTinley Park, United States
  • Velocity Clinical Research, WacoWaco, United States
  • MedVadis Research CorporationWaltham, United States
  • Velocity Clinical Research, Washington DCWashington D.C., United States
  • Velocity Clinical Research, Salt Lake CityWest Jordan, United States
  • AMR Wichita East, KS (Heartland Research Associates)Wichita, United States
  • Carolinas Pain Institute - Winston-Salem OfficeWinston-Salem, United States
  • Conquest Clinical Research (Winter Park)Winter Park, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.

The group in the trial

  • Suzetrigine (SUZ)Treatment being tested

    Participants will receive SUZ once daily (qd) up to 52 weeks.

    Treatment: Suzetrigine

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Record updated
30 October 2026